title: The flip side of doxorubicin: Inflammatory and tumor promoting cytokines.
abstract: Cardiac toxicity is a major dose-limiting factor for the anthracycline drug doxorubicin. The reasons why doxorubicin causes heart damage are not fully understood, and the manuscript by Wong et al. postulates that inflammatory cytokines released from macrophages or other cell types may play a significant role in the damage process in response to doxorubicin and possibly other chemotherapeutic agents.(1) Expression of many cytokines requires activation of both the p38 MAPK and JNK pathways and, additionally, doxorubicin toxicity can be blocked by combined inhibition of both pathways.(2,3) The MAP3K responsible for doxorubicin-induced p38 MAPK and JNK activation in keratinocytes was previously shown by these authors to be ZAK.(4) ZAK is of note because it can be targeted by FDA approved agents such as nilotinib and sorafenib.(4-7)
authors: Department of Neurosurgery; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.
authors: Paul
authors: P
authors: Dent
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D004317:Doxorubicin / Q000633:toxicity*; D007249:Inflammation / Q000201:enzymology*; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*
chemical_list: D000903:Antibiotics, Antineoplastic; D047428:Protein Kinase Inhibitors; D004317:Doxorubicin; D020930:MAP Kinase Kinase Kinases
keywords: MAPK; ZAK; cytokines; doxorubicin; nilotinib; ponatinib; sorafenib
references: Biochim Biophys Acta. 2010 Mar;1804(3):445-53
references: 19922818
references: Cancer Biol Ther. 2011 Jun 15;11(12):1008-16
references: 21464611
references: Nat Biotechnol. 2011 Oct 30;29(11):1046-51
references: 22037378
references: Gastroenterology. 2011 Sep;141(3):e19-20; author reply e20-1
references: 21794834
references: Cell Res. 2011 Jan;21(1):159-68
references: 21187858
references: J Immunol. 1999 May 1;162(9):5367-73
references: 10228013
references: Cancer Biol Ther. 2010 Aug 1;10(3):258-66
references: 20559024
references: PLoS One. 2012;7(5):e37735
references: 22662203
references: Cancer Biol Ther. 2008 Apr;7(4):587-93
references: 18379195
references: Cancer Biol Ther. 2013 Jan;14(1):56-63
references: 23114643
references: Nat Biotechnol. 2008 Jan;26(1):127-32
references: 18183025